Goetz MP, O'Shaughnessy J, Sledge Jr., et al. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies. SABCS 2017, GS6-02.
Apixaban niet inferieur aan dalteparine bij kankergeassocieerde VTE
jun 2020 | Benigne hematologie